Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336
Rank in Stocks
#3775
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
Share Price
$4.87
Market Cap
$4.36B
Change (1 day)
-5.47%
Change (1 year)
-15.62%
Country
CN
Trade Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Category
Healthcare
Stock price history for Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Highest end of day price: $5.19 on 2026-10-01
Lowest end of day price: $4.81 on 2020-07-01
Lowest end of day price: $4.81 on 2020-07-01
Stock price history of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd from 2020 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | 6.67% |
| 2025 | 188.76% |
| 2024 | -5.91% |
| 2023 | 62.34% |
| 2022 | -30.84% |
| 2021 | -25.95% |
| 2020 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $536.98 | 25.92% |
US
|
|
| $224.77 | 737.11% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $876.75 | 7.69% |
NL
|
